Alex J Rai

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Cancer proteomics: Serum diagnostics for tumor marker discovery
    Alex J Rai
    Department of Pathology, Division of Clinical Chemistry, and Center for Biomarker Discovery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Ann N Y Acad Sci 1022:286-94. 2004
  2. ncbi HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples
    Alex J Rai
    The Johns Hopkins University School of Medicine, Department of Pathology, Division of Clinical Chemistry, Baltimore, MD 21287 7065, USA
    Proteomics 5:3262-77. 2005
  3. ncbi Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of
    Alex J Rai
    Department of Pathology, Division of Clinical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21287 7065, USA
    Proteomics 5:3467-74. 2005
  4. ncbi Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
  5. ncbi Proteomic approaches to tumor marker discovery
    Alex J Rai
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Arch Pathol Lab Med 126:1518-26. 2002
  6. ncbi [Abundant protein' depletion in search of biomarkers]
    Alex J Rai
    Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Med Sci (Paris) 23:5-8. 2007
  7. ncbi Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics
    Alex J Rai
    Memorial Sloan Kettering Cancer Center, Department of Clinical Laboratories, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Expert Rev Proteomics 3:409-26. 2006
  8. ncbi Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry
    Mark D Schuchard
    Sigma-Aldrich Biotechnology, St. Louis, MO 63178, USA
    Biotechniques 39:239-47. 2005
  9. ncbi Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database
    Gilbert S Omenn
    Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0656, USA
    Proteomics 5:3226-45. 2005
  10. ncbi Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays
    Alex J Rai
    Memorial Sloan Kettering Cancer Center, Department of Clinical Laboratories, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Expert Rev Mol Diagn 7:545-53. 2007

Detail Information

Publications10

  1. ncbi Cancer proteomics: Serum diagnostics for tumor marker discovery
    Alex J Rai
    Department of Pathology, Division of Clinical Chemistry, and Center for Biomarker Discovery, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Ann N Y Acad Sci 1022:286-94. 2004
    ..This technology can be successfully applied to clinical specimens for the identification of new tumor markers...
  2. ncbi HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples
    Alex J Rai
    The Johns Hopkins University School of Medicine, Department of Pathology, Division of Clinical Chemistry, Baltimore, MD 21287 7065, USA
    Proteomics 5:3262-77. 2005
    ..These findings help provide guidance on sample handling issues, with the overall suggestion being to be conscious of all possible pre-analytical variables as a prerequisite of any proteomic study...
  3. ncbi Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of
    Alex J Rai
    Department of Pathology, Division of Clinical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21287 7065, USA
    Proteomics 5:3467-74. 2005
    ..This approach could be exploited for population-based studies in all phases of the HUPO PPP...
  4. ncbi Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
    ..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer...
  5. ncbi Proteomic approaches to tumor marker discovery
    Alex J Rai
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Arch Pathol Lab Med 126:1518-26. 2002
    ..Additional studies are required to further validate these biomarkers...
  6. ncbi [Abundant protein' depletion in search of biomarkers]
    Alex J Rai
    Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Med Sci (Paris) 23:5-8. 2007
    ..Finally, considerations for the translation of biomarkers, identified in such a manner, to a clinically useful assay, are discussed...
  7. ncbi Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics
    Alex J Rai
    Memorial Sloan Kettering Cancer Center, Department of Clinical Laboratories, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Expert Rev Proteomics 3:409-26. 2006
    ..In this article, we will review preanalytical variables, provide examples for their effects on the determination of distinct peptides and proteins and discuss potential implications for clinical proteomics investigations...
  8. ncbi Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry
    Mark D Schuchard
    Sigma-Aldrich Biotechnology, St. Louis, MO 63178, USA
    Biotechniques 39:239-47. 2005
    ..A model is proposed for the random or stochastic coupling of AEBSF-derived moieties to serine and/or tyrosine residues throughout apo A1 and potentially other plasma proteins...
  9. ncbi Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database
    Gilbert S Omenn
    Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0656, USA
    Proteomics 5:3226-45. 2005
    ....
  10. ncbi Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays
    Alex J Rai
    Memorial Sloan Kettering Cancer Center, Department of Clinical Laboratories, 1275 York Avenue, Box 88, New York, NY 10021, USA
    Expert Rev Mol Diagn 7:545-53. 2007
    ..Finally, regulatory considerations that need to be addressed before a biomarker assay is commercialized are discussed briefly...